Physician profile
Dawn Comrie
NPI 1508853391
$1,037.34
in general payments reported to CMS, 2019-2025
18 companies · $99.86 in 2025
The $99.86 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $354 · 2022: $259 · 2023: $325 · 2025: $99.86.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $425.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $424.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $224.32 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $144.45 | 2021-2025 | Farxiga, Airsupra |
| Pfizer INC. | $105.63 | 2021-2025 | |
| Glaxosmithkline, LLC. | $101.61 | 2021-2023 | Trelegy Ellipta |
| Lilly USA, LLC | $83.99 | 2022-2023 | Mounjaro |
| Myriad Women'S Health, INC. | $57.56 | 2023 | Myrisk |
| Kowa Pharmaceuticals America, INC. | $49.63 | 2023 | Seglentis, Livalo |
| Abbott Laboratories | $43.01 | 2022-2023 | Freestyle Libre 2 |
| Medtronic, INC. | $36.42 | 2025 | Minimed 780g |
| Shield Therapeutics INC | $29.63 | 2023 | Accrufer |
| Novo Nordisk INC | $24.84 | 2025 | Ozempic |
| Alk-Abello, INC | $23.87 | 2022 | |
| Astellas Pharma US INC | $21.18 | 2021 | |
| Amgen INC. | $21.13 | 2021 | |
| Organon LLC | $20.20 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $18.91 | 2022 | |
| Idorsia Pharmaceuticals US INC | $15.90 | 2023 | Quviviq |
| Novartis Pharmaceuticals Corporation | $15.06 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dawn Comrie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.